Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer, characterized by overexpression of the HER2 protein or amplification of the HER2 gene, accounts for approximately 15%–20% of all breast cancer cases [1]. This evidence concerns the gene ERBB2 and breast cancer.